UK markets open in 7 hours 41 minutes
  • NIKKEI 225

    0.00 (0.00%)

    -77.11 (-0.40%)

    +0.33 (+0.44%)

    +0.20 (+0.01%)
  • DOW

    -350.76 (-1.03%)

    -5.88 (-0.04%)
  • CMC Crypto 200

    -1.32 (-0.33%)
  • ^IXIC

    -225.05 (-2.00%)
  • ^FTAS

    -28.73 (-0.69%)

Global In Vivo CRO Market Report 2022: Increase in Offshoring Medical Device Manufacturing to Emerging Countries Driving Growth

Company Logo
Company Logo

Global In Vivo CRO Market

Global In Vivo CRO Market
Global In Vivo CRO Market

Dublin, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The "Global In Vivo CRO Market Size, Share & Trends Analysis Report by Type (Rodent, Non-Rodent), by GLP Type (Non-GLP, GLP Toxicology), by Indication (Pain Management, Oncology), by Region (North America, APAC), and Segment Forecasts, 2022-2030" report has been added to's offering.

The global in vivo CRO market size is expected to reach USD 7.92 billion by 2030, registering a CAGR of 8.2% It is expected to expand at a CAGR of 8.5% during the forecast period. Increasing focus on core competencies by the pharmaceutical players coupled with economic efficiency offered for outsourcing is expected to boost the demand.

In Addition, the CROs are equipped with a competent workforce capable of performing a diverse number of tasks along with being well-versed through regulatory requirements. Also, the pressure from the increasing competition owing to the rapid growth of generics, patent expirations, and introduction of biosimilar equivalents are encouraging pharmaceutical companies to take the aid of such organizations.

Increasing mergers and collaborations have propelled the value of pharmaceutical outsourcing with major industry contributors expanding into developing regions. The year 2015 experienced high valued transactions as a result of LabCorp acquiring Covance for USD 5.5 billion and the Chinese Private Equity Group acquiring WuXifor for USD 3.3 billion. The patent cliff, high research and development cost involved, and globalization in the clinical trial process has driven the

In Vivo CRO Market Report Highlights

  • Rodent-based In vivo CRO led the market in 2018 and is anticipated to remain dominant throughout the forecast period. Mice are the most used animal for preclinical evaluation and accounted for almost 76% of the market share in 2018..

  • Based on indication, oncology held the largest market share in 2018, attributed to the increasing number of cancer cases and the focus of pharmaceutical players on introducing novel drug treatments with fewer side-effects.

  • North America led the global In vivo CRO market in 2018 owing to the presence of technologically advanced CROs.

  • Asia Pacific is anticipated to register the fastest CAGR over the forecast period. Constantly improving healthcare infrastructure, huge patient base, presence of untapped opportunities, and economic development, are some factors responsible for the rapid growth.

Market Dynamics

Market Drivers

  • Changing Regulatory Landscape

  • Increase in Offshoring Medical Device Manufacturing to Emerging Countries

  • Rising Demand for Advanced Products

  • Implementation of International Standards by Contract Manufacturers

  • Rising Price Competition and Requirement to Reduce Cost

  • Increasing Complexity Concerning Product Design and Engineering

Market Restraints

  • Compliance Issues while Outsourcing

  • Changing Scenarios in Developing Countries

  • Regulatory and Legal Compliance

  • Contractual Obligation

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. In Vivo CRO Market Variables, Trends & Scope

Chapter 4. In Vivo CRO Market: Type Segment Analysis

Chapter 5. In Vivo CRO Market: GLP Type Segment Analysis

Chapter 6. In Vivo CRO Market: Indication Segment Analysis

Chapter 7. In Vivo CRO Market: Regional Analysis

Chapter 8. Competitive Landscape

Companies Mentioned

  • Quintiles

  • Charles River Laboratories

  • Icon Plc

  • Covance Inc

  • Paraxel International

  • Pharmaceutical Product Development (PPD)

  • Theorem Clinical Research

  • InVentiv Health

  • Wuxi AppTec, Inc



For more information about this report visit


CONTACT: CONTACT: Laura Wood,Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900